Thalidomide therapy for Crohn's disease [1]

Gastroenterology

Volumn 119, Issue 2, 2000, Pages 596-

  Fishman, S J ^a   Feins, N R ^a   D'Amato, R J ^a   Folkman, J ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; THALIDOMIDE; TUMOR NECROSIS FACTOR; VASCULOTROPIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANGIOGENESIS; CASE REPORT; CROHN DISEASE; DOSE RESPONSE; DRUG MECHANISM; ERYTHEMA NODOSUM; FEMALE; HUMAN; LEPROSY; LETTER; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; SKIN DEFECT; TERATOGENICITY; NOTE;

CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; THALIDOMIDE;

EID: 0034242844     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.16152     Document Type: Article

References (8)

1. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
2. An open-label pilot study of low-dose thalidomide in chronically active, steroid dependent Crohn's disease
3. New life in a sleeper: Thalidomide and Crohn's disease
4. Thalidomide is an inhibitor of angiogenesis
5. Long-term remission of Crohn's disease treatment with thalidomide: The seminal case
6. Serum basic fibro blast growth factor in pediatric Crohn's disease: Implications for wound healing
7. Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease
8. Angiogenesis and inflammation